Amicus Therapeutics Inc
(FRA:AM6)
€
9.05
0.05 (0.56%)
Market Cap: 2.79 Bil
Enterprise Value: 2.99 Bil
PE Ratio: 0
PB Ratio: 22.90
GF Score: 72/100 - Q4 2023 Amicus Therapeutics Inc Earnings Call TranscriptFeb 28, 2024€12.7 (+0.79%)Earnings
- Amicus Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Amicus Therapeutics Inc at UBS BioPharma Conference TranscriptNov 09, 2023
- Q3 2023 Amicus Therapeutics Inc Earnings Call TranscriptNov 08, 2023€10.8 (+3.85%)Earnings
- Amicus Therapeutics Inc to Discuss the FDA Approval Call TranscriptSep 28, 2023
- Amicus Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Q2 2023 Amicus Therapeutics Inc Earnings Call TranscriptAug 08, 2023€11.3 (-5.04%)Earnings
- Amicus Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Q1 2023 Amicus Therapeutics Inc Earnings Call TranscriptMay 10, 2023€11.1 (+0.91%)Earnings
- Q4 2022 Amicus Therapeutics Inc Earnings Call TranscriptMar 01, 2023€12.27 (+0.62%)Earnings
- Amicus Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Q3 2022 Amicus Therapeutics Inc Earnings Call TranscriptNov 07, 2022€10.03 (-2.64%)Earnings
- Amicus Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Q2 2022 Amicus Therapeutics Inc Earnings Call TranscriptAug 04, 2022€10.04 (-0.18%)Earnings
- Amicus Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Amicus Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Q1 2022 Amicus Therapeutics Inc Earnings Call TranscriptMay 09, 2022€6.08 (-1.76%)Earnings
- Q4 2021 Amicus Therapeutics Inc Earnings Call TranscriptFeb 24, 2022€7.05 (-6.62%)Earnings
- Amicus Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Q3 2021 Amicus Therapeutics Inc Earnings Call TranscriptNov 09, 2021€9.9 (-4.81%)Earnings
- Amicus Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 30, 2021
- Amicus Therapeutics Inc and ARYA Sciences Acquisition IV Corp to Announce Formation of a Next-Generation Genetic Medicine Company Call TranscriptSep 29, 2021
- Amicus Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Amicus Therapeutics Inc Earnings Call TranscriptAug 05, 2021€8.1 (+4.52%)Earnings
- Amicus Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Amicus Therapeutics Inc at UBS Global Healthcare Virtual Conference TranscriptMay 24, 2021
- Amicus Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 12, 2021
- Q1 2021 Amicus Therapeutics Inc Earnings Call TranscriptMay 10, 2021€7.95 (+0.63%)Earnings
- Q4 2020 Amicus Therapeutics Inc Earnings Call TranscriptMar 01, 2021€10.1 (+4.66%)Earnings
- Amicus Therapeutics Inc to Discuss the Topline PROPEL Results - Conference Call TranscriptFeb 11, 2021
- Amicus Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Amicus Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 09, 2020
- Q3 2020 Amicus Therapeutics Inc Earnings Call TranscriptNov 05, 2020€17.6 (+8.64%)Earnings
- Amicus Therapeutics Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) TranscriptSep 18, 2020
- Amicus Therapeutics Inc at Citi BioPharma Conference (Virtual) TranscriptSep 10, 2020
- Q2 2020 Amicus Therapeutics Inc Earnings Call TranscriptAug 10, 2020€12.9 (+0.78%)Earnings
- Amicus Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Q1 2020 Amicus Therapeutics Inc Earnings Call TranscriptMay 07, 2020€10.9 (-1.80%)Earnings
- Q4 2019 Amicus Therapeutics Inc Earnings Call TranscriptMar 02, 2020€8.05 (-2.42%)Earnings
- Amicus Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- Q3 2019 Amicus Therapeutics Inc Earnings Call TranscriptNov 11, 2019€8.6 (+8.86%)Earnings
- Amicus Therapeutics Inc Analyst Day TranscriptOct 10, 2019
- Q2 2019 Amicus Therapeutics Inc Earnings Call TranscriptAug 08, 2019€10.39 (+0.39%)Earnings
- Amicus Therapeutics Inc Presents Positive Interim Clinical Data for CLN6 Batten Disease Conference Call TranscriptAug 01, 2019
- Amicus Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2019
- Amicus Therapeutics Inc and the University of Pennsylvania Expansion of Gene Therapy Collaboration - Call TranscriptMay 29, 2019
- Amicus Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 14, 2019
- Q1 2019 Amicus Therapeutics Inc Earnings Call TranscriptMay 08, 2019€12.01 (-2.99%)Earnings
- Amicus Therapeutics Inc to Discuss the Preclinical Data Presented at ASGCT - Call TranscriptApr 30, 2019
- Amicus Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 12, 2019
- Q4 2018 Amicus Therapeutics Inc Earnings Call TranscriptFeb 28, 2019€10.96 (+4.88%)Earnings
- Amicus Therapeutics Inc to Discuss the Clinical Pompe Disease Data and Preclinical Batten Disease Data Presented at the WORLDSymposium TranscriptFeb 07, 2019
Amicus Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 12, 2019 / 12:00PM GMT
Release Date Price:
€11.82
(+3.32%)
Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst
Well, good morning, everyone. It's my distinct pleasure to start us off with the conference here with certainly one of the more uplifting stories, I think, in all of biotech, but joining me today from Amicus Therapeutics is Daphne Quimi and Jeff Castelli. Thank you so much for joining us.
Jeffrey P. Castelli
Amicus Therapeutics, Inc. - Chief Portfolio Officer & Head of Gene Therapy
Thank you.
Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst
My name is Jason Zemansky. I am an associate on Geoff Meacham's team, large cap biopharma analyst at Barclays.
So I think we should just dive into the questions.
Questions & Answers
Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst
So certainly, a large milestone in Amicus' story was the commercial approval of Galafold last August. Can you tell us a little bit about the feedback
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)